-+ 0.00%
-+ 0.00%
-+ 0.00%

Ocular Therapeutix Will Host A Webcast To Review The Topline Results Of The SOL-1 Phase 3 Superiority Clinical Trial Of AXPAXLI For The Treatment Of Wet Age-Related Macular Degeneration, On Tuesday, February 17, 2026

Benzinga·02/13/2026 22:09:50
Listen to the news

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between February 25 – 28, 2026.